Some pregnant women and infants have received the wrong RSV. Blows
Doctors and pharmacists seem confused by the guidelines. And the brands don't help.
This winter, for the first time, two vaccines were available to ward off the respiratory syncytial virus, which is particularly dangerous for health. the elderly and infants. Only one of them – Abrysvo, made by Pfizer – was approved for pregnant women, and none of them were approved for young children.
The distinction apparently escaped some clinicians and pharmacists. At least 128 pregnant women were mistakenly given the alternative vaccine – Arexvy, from GSK – and at least 25 children of under 2s have been vaccinated, according to the Centers for Disease Control and Prevention. has warned.
Dr. Sarah Long, a professor of pediatrics at Drexel University College of Medicine and an advisor to the agency, said she was "blindsided" by the reports. "It's very upsetting that this is happening," she said.
Arexvy has not been tested on pregnant women or children, Information on its effects in these groups is therefore limited. . No serious harm from these errors has yet been confirmed, but the outcome was unknown in the majority of reported cases.
Based on available data, the Dr. Long said she was most concerned about young children who received R.S.V. vaccine than pregnant women who received Arexvy or their babies. Evidence from animal testing “strongly suggests” that Arexvy may exacerbate RSV. infection in children under 2 years old, rather than mitigating it, according to the Food and Drug Administration.
To prevent this, the C.D.C. recommended that children who mistakenly received either vaccine also receive nirsevimab (sold as Beyfortus), a monoclonal antibody that provides strong immune protection, while R.S.V. the season lasts.
We are having difficulty retrieving the content of the article.
Please enable JavaScript in the your browser settings.
p>
Thank you for your patience while we verify access. If you are in Reader mode, please exit and log in to your Times account, or subscribe to the entire Times.
Doctors and pharmacists seem confused by the guidelines. And the brands don't help.
This winter, for the first time, two vaccines were available to ward off the respiratory syncytial virus, which is particularly dangerous for health. the elderly and infants. Only one of them – Abrysvo, made by Pfizer – was approved for pregnant women, and none of them were approved for young children.
The distinction apparently escaped some clinicians and pharmacists. At least 128 pregnant women were mistakenly given the alternative vaccine – Arexvy, from GSK – and at least 25 children of under 2s have been vaccinated, according to the Centers for Disease Control and Prevention. has warned.
Dr. Sarah Long, a professor of pediatrics at Drexel University College of Medicine and an advisor to the agency, said she was "blindsided" by the reports. "It's very upsetting that this is happening," she said.
Arexvy has not been tested on pregnant women or children, Information on its effects in these groups is therefore limited. . No serious harm from these errors has yet been confirmed, but the outcome was unknown in the majority of reported cases.
Based on available data, the Dr. Long said she was most concerned about young children who received R.S.V. vaccine than pregnant women who received Arexvy or their babies. Evidence from animal testing “strongly suggests” that Arexvy may exacerbate RSV. infection in children under 2 years old, rather than mitigating it, according to the Food and Drug Administration.
To prevent this, the C.D.C. recommended that children who mistakenly received either vaccine also receive nirsevimab (sold as Beyfortus), a monoclonal antibody that provides strong immune protection, while R.S.V. the season lasts.
We are having difficulty retrieving the content of the article.
Please enable JavaScript in the your browser settings.
p>
Thank you for your patience while we verify access. If you are in Reader mode, please exit and log in to your Times account, or subscribe to the entire Times.
What's Your Reaction?
